Inhaled Corticosteroid Plus Long-Acting Beta2-Agonist Therapy Is Overused In The Treatment Of Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analyses Of Two 1-Year…
H Watz, GT Ferguson, L Grönke, F Voss, R Abrahams, R Buhl · Pneumologie · 2016 · Heft 02
Bibliografische Angaben
Zusammenfassung
Rationale: Inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) therapy is indicated for different patient groups with chronic obstructive pulmonary disease (COPD) in the US and Europe. In the previous version of the Global initiative for chronic Obstructive Lung Disease (GOLD) recommendations, the use of ICS plus LABA therapy was restricted to patients with severe and very severe lung-function impairment and frequent exacerbations, with overtreatment in milder patient populations well documented. The current GOLD document recommends the use of ICS plus LABA maintenance therapy for patients in categor…